Nomenclature
Short Name:
TESK2
Full Name:
Dual specificity testis-specific protein kinase 2
Alias:
- Testicular protein kinase 2
Classification
Type:
Protein-serine/threonine kinase
Group:
TKL
Family:
LISK
SubFamily:
TESK
Structure
Mol. Mass (Da):
63,639
# Amino Acids:
571
# mRNA Isoforms:
3
mRNA Isoforms:
63,639 Da (571 AA; Q96S53); 61,887 Da (555 AA; Q96S53-2); 60,332 Da (542 AA; Q96S53-3)
4D Structure:
NA
1D Structure:
Subfamily Alignment
Domain Distribution:
| Start | End | Domain |
|---|---|---|
| 58 | 335 | Pkinase |
Distribution
Based on gene microarray analysis from the NCBI
Human Tissue Distribution
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
56
567
19
762
5
52
13
66
15
148
1
0
42
426
49
548
61
618
17
633
16
166
44
293
27
277
22
457
100
1008
23
1786
30
300
13
294
8
82
48
57
9
95
17
117
62
628
98
664
12
116
12
19
6
64
12
53
5
49
14
52
5
52
8
20
8
80
102
62
10
101
11
94
14
141
46
89
62
621
59
617
13
134
13
133
7
68
15
62
20
204
2
91
15
151
11
137
6
58
13
51
65
656
31
720
7
75
18
42
9
95
11
100
5
52
11
58
47
473
14
259
87
880
18
595
59
597
21
695
6
59
51
128
96
966
26
814
19
189
22
103
Evolution
Species Conservation
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
100
100
100
99.8
100
100
92.9
95
-
-
-
91
-
-
84
91
94.4
91
-
-
-
87.7
90.7
88
89.8
92.4
90
-
-
-
69
74.9
-
-
-
80
-
-
75
60
68.7
72
-
-
-
-
-
-
25.6
35.7
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
For a wider analysis go to PhosphoNET Evolution in PhosphoNET
Binding Proteins
Examples of known interacting proteins
hiddentext
| No. | Name – UniProt ID |
|---|---|
| 1 | DSTN - P60981 |
Regulation
Activation:
Activated by autophosphorylation on Ser-219
Inhibition:
NA
Synthesis:
NA
Degradation:
NA
Known Downstream Substrates
For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET
predictions.
Based on in vitro and/or in vivo phosphorylation data
| Substrate Short Name | UniProt ID (Human) | Phosphosite Location | Phosphosite Sequence | Effect of Phosphorylation |
|---|
Protein Kinase Specificity
Matrix of observed frequency (%) of amino acids in aligned protein substrate phosphosites
Matrix Type:
Predicted from the application of the Kinexus Kinase Substrate Predictor Version 2.0 algorithm, which was trained with over 10,000 kinase-protein substrate pairs and 8,000 kinase-peptide substrate pairs.
Domain #:
1
Disease Linkage
Gene Expression in Cancers:
The COSMIC website notes an up-regulated expression score for TESK2 in diverse human cancers of 476, which is close to the average score of 462 for the human protein kinases. The down-regulated expression score of 23 for this protein kinase in human cancers was 0.4-fold of the average score of 60 for the human protein kinases.
Mutagenesis Experiments:
Insertional mutagenesis studies in mice have not yet revealed a role for this protein kinase in mouse cancer oncogenesis.
Mutation Rate in All Cancers:
Percent mutation rates per 100 amino acids length in human cancers: 0.07 % in 25015 diverse cancer specimens. This rate is only -4 % lower and is very similar to the average rate of 0.075 % calculated for human protein kinases in general.
Mutation Rate in Specific Cancers:
Highest percent mutation rates per 100 amino acids length in human cancers: 0.38 % in 603 endometrium cancers tested; 0.37 % in 1294 large intestine cancers tested; 0.21 % in 589 stomach cancers tested; 0.16 % in 864 skin cancers tested; 0.14 % in 127 biliary tract cancers tested; 0.1 % in 1822 lung cancers tested; 0.1 % in 1393 breast cancers tested; 0.09 % in 942 upper aerodigestive tract cancers tested; 0.07 % in 710 oesophagus cancers tested; 0.06 % in 833 ovary cancers tested; 0.06 % in 548 urinary tract cancers tested; 0.06 % in 273 cervix cancers tested; 0.05 % in 382 soft tissue cancers tested; 0.05 % in 1459 pancreas cancers tested; 0.03 % in 1512 liver cancers tested; 0.03 % in 1276 kidney cancers tested; 0.02 % in 881 prostate cancers tested; 0.02 % in 2082 central nervous system cancers tested; 0.02 % in 2009 haematopoietic and lymphoid cancers tested.
Frequency of Mutated Sites:
None > 4 in 20,299 cancer specimens
Comments:
Only 3 deletions, and no insertions or complex mutations are noted on the COSMIC website.